Please login to the form below

Not currently logged in
Email:
Password:

multiple sclerosis

This page shows the latest multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.

FDA rejects Sarepta’s new Duchenne drug over safety fears

FDA rejects Sarepta’s new Duchenne drug over safety fears

The company is also investing in gene therapies for DMD and a range of other rare diseases as well as multiple sclerosis.

Latest news

  • Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

    including cancer, multiple sclerosis, influenza and blindness” on her watch. ... He will be tasked with adding to Roche’s growth products, like Ocrevus for multiple sclerosis and Hemlibra for haemophilia, with a string of 16 new molecular entity (NME)

  • BMS buoyed by FDA approval of Celgene’s myelofibrosis drug BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

    Fedratinib was one of the late-stage development programmes highlighted by BMS when the merger was announced in January, although others – such as multiple sclerosis drug ozanimod and CAR-T cancer

  • Triplet approvals for myeloma boost Celgene in Q2 Triplet approvals for myeloma boost Celgene in Q2

    Revlimid gained on the back of its recent approval alongside Takeda’s Velcade (bortezomib) and dexamethasone as a first-line therapy for adults with multiple myeloma who are not eligible for ... Also nearing the market are fedratinib for myelofibrosis

  • Tecfidera successor’s side-effect profile boosts Biogen Tecfidera successor’s side-effect profile boosts Biogen

    But analysts unconvinced that patients will switch. Biogen’s flagship multiple sclerosis franchise has been given a major boost thanks to safety data from its follow-on to blockbuster Tecfidera. ... The drug is Biogen’s biggest earner by some way,

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    Squibb got the go-ahead for Empliciti (elotuzumab) alongside Celgene’s Pomalyst (pomalidomide) and dexamethasone for relapsed/refractory multiple myeloma, based on the ELOQUENT-3 trial. ... Finally, the panel recommended that Novartis’ multiple

More from news
Approximately 78 fully matching, plus 470 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow ... EvaluatePharma has predicted it could become a nearly $2.5bn

  • Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available? Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?

    In the past, specialised infusion centres have been established to provide outpatient infusion therapy administered by nurses to multiple sclerosis patients in Germany.

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    The Accelerated Access Collaborative. Ewan Barbour, Market Access and Pricing Director, Merck, presented on its multiple sclerosis treatment Mavenclad being selected to be among the first designated Rapid Uptake products on

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    Even with the drive towards Integrated Cares Systems (ICSs) across England, the reality is that the industry will still have to deal with multiple, independent NHS organisations when negotiating a joint ... The company has just secured 'Rapid Uptake'

  • Tackling a formidable foe Tackling a formidable foe

    Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis. ... It is easy to get the impression that the quest for advanced multiple sclerosis treatments, and eventually a cure, is on cruise control.

More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 14 fully matching, plus 25 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Patient Involvement in Health Technology Assessment
Exploring the evolution of patient involvement in health technology assessment (HTA), and the role of the patient voice in market access....

Infographics